A competitive ligand binding assay asks whether a test ligand can displace a reference ligand from a written site. It does not elucidate binding mechanisms or biological functions, and it does not pinpoint critical binding sites. The usable file is a displacement curve. The first fitted number is usually an IC50. A Ki can be calculated from that IC50 when Cheng–Prusoff assumptions hold. That Ki is not interchangeable with the test ligand’s Kd, and relative affinities do not directly determine the outcome of every mixture.
The reference ligand is often labeled, or it is a well-characterized unlabeled competitor in an optical format. The macromolecule can be a protein, a receptor construct, or, in a rewritten design, a nucleic acid. Competition with DNA or RNA is allowed only when that polymer is the written target. Protein–protein competition is a different assay. Researchers who already have a reference ligand and a test series and need a displacement file can review the MtoZ Biolabs Competitive Ligand Binding Assay Service for project-specific format matching.
Displacement Is Not a Site Map
Proteins can have a pocket that a reference ligand occupies. A test ligand that reduces the reference signal may share that pocket, bind an overlapping pose, or change the pocket allosterically. Incomplete displacement is a warning, not a failed run. Site specificity is a later claim. Mutagenesis tests a residue. Docking predicts a pose. Neither confirms the binding site as a structural proof of the competition curve.
A receptor heading is a different page. Ligand-receptor analysis names the pair. This page names the competition format. For that claim-versus-file split, Ligand-Receptor Analysis is the complementary receptor page.
Chemical proteomics can also run a parent compound against a covalent probe. That is a competed labeling ratio, not this assay. Do not import a probe table into a displacement curve.
Workflow Reads as Curve Construction
Sample preparation
A purified protein, a membrane or lysate that still displays the target, or an immobilized nucleic acid can be the macromolecule. Stability and a functional check matter for the format. They do not ensure accurate competition analysis. The reference ligand needs a known saturation behavior, including its own Kd when a Ki will be calculated. A high-affinity label that changes the pocket is a different ligand from the unlabeled parent.
Binding assay
A concentration series of the test ligand is added to a mixture of reference ligand and target. Equilibrium formats, including many fluorescence-polarization (FP) and radioligand designs, are read after a written incubation. They are not real-time monitoring as a class. Surface plasmon resonance (SPR) can record competition during a flow. Mass spectrometry can report a selected ligand or an intact-mass occupancy. An MS peak change is not, by itself, a competitive ligand binding assay.
Non-specific binding of the reference ligand has to be defined, usually with a saturating unlabeled reference. Ionic strength and detergent can change that floor. They do not minimize non-specific interactions as a general fix.
Data analysis
The inhibition curve is fitted for an IC50 under a written model. A one-site model is not automatic. A Ki follows Cheng–Prusoff when the ligands compete reversibly at one site, the reference concentration and Kd are known, and the system is at equilibrium. Fitting the same points as a Kd of the test ligand is not allowed by default. An irreversible or covalent test ligand breaks that conversion.
Figure 1. Reference ligand occupies a written site. Test ligand reduces that signal. IC50 is the fitted midpoint. Ki is a later conversion. Kd of the test ligand is not the same number.
Write the reference ligand, its Kd, and the non-specific floor before converting IC50 to Ki.
What the Applications Cannot Buy
Drug development remains an allowable background. Comparing IC50 values of a series against one reference ranks that series under those conditions. It does not screen and optimize candidates, and it does not refine lead activity.
Target identification is not a granted use. Displacement of a reference from a known target can support the sentence that the test ligand affects that occupancy. It does not validate that a novel compound interacts with known targets, and it does not elucidate a new target.
Mechanistic studies of transcription-factor–DNA binding are a later nucleic-acid design. This assay does not unravel binding dynamics or molecular interactions as a class.
High specificity and sensitivity do not attach to the heading. Real-time signal monitoring belongs to the formats that actually record a time course. Versatility across protein–small molecule, protein–protein, and nucleic acid–ligand interactions is a catalog remark, not a property of one protocol. Efficiency that accelerates drug screening is a slogan.
Figure 2. A steeper or left-shifted curve ranks displacement of that reference. Docking and mutagenesis are later files. Chemical proteomics competition is a different table.
Experimental Limits
This page reduces the assay to one reference, one test series, and one fitted IC50. Precise quantitative insights, biological function, and chemical proteomics as the related service sit outside ordinary research reporting. A probe-enrichment table does not answer a displacement question.
Allosteric ligands, ligand depletion, and two-site models remain reasons that a clean Cheng–Prusoff Ki may not exist. Those limits are why the request has to name the model before the first plate.
Figure 3. Keep: a reference ligand, a displacement series, IC50, and a Ki only when assumptions hold. Not granted: interchangeable Kd, site confirmation by docking, PPI versatility, or chemical proteomics as the next step.
Project Planning and Service Scope
A usable request names the macromolecule, the reference ligand and its label, the test series, how non-specific binding will be defined, and whether the deliverable is an IC50 or a Cheng–Prusoff Ki. MtoZ Biolabs scopes competitive formats on FP, radioligand, or SPR arms when those arms match the written question. Interpretability still follows the curve and the assumptions, not a high-specificity heading.
Once the next sentence is a labeled-or-unlabeled binding menu rather than a displacement curve, this competition page should hand off. Researchers who need that menu can review the MtoZ Biolabs Ligand Binding Assay Service for project-specific sample evaluation, feasibility assessment, and workflow planning.
Frequently Asked Questions
1. Does a competitive assay measure the test ligand’s Kd?
Not as a default. It fits an IC50. A Ki is a conversion under named assumptions.
2. Does displacement pinpoint the binding site?
It reports loss of the reference signal. A site is a later structural or mutagenesis file.
3. Are FP, SPR, and MS interchangeable real-time readouts?
FP is often an equilibrium polarization. SPR can be a sensorgram. An MS peak is not this assay by default.
4. Can the same protocol cover protein–protein competition?
Not as a class. That is a different format.
5. Is chemical proteomics the related service?
No. A competed probe table is not a displacement curve.
Reference
- Cheng Y., Prusoff W.H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108. https://doi.org/10.1016/0006-2952(73)90196-2
- Hulme E.C., Trevethick M.A. (2010). Ligand binding assays at equilibrium: validation and interpretation. Br. J. Pharmacol., 161, 1219-1237. https://doi.org/10.1111/j.1476-5381.2010.00831.x
- Motulsky H.J., Neubig R.R. (2010). Analyzing binding data. Curr. Protoc. Neurosci., Chapter 7, Unit 7.5. https://doi.org/10.1002/0471142301.ns0705s52
- Lea W.A., Simeonov A. (2011). Fluorescence polarization assays in small molecule screening. Expert Opin. Drug Discov., 6, 17-32. https://doi.org/10.1517/17460441.2011.537322
